These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 26897742)

  • 1. Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population.
    Ciccarelli C; Vulcano F; Milazzo L; Gravina GL; Marampon F; Macioce G; Giampaolo A; Tombolini V; Di Paolo V; Hassan HJ; Zani BM
    Mol Cancer; 2016 Feb; 15():16. PubMed ID: 26897742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.
    Ciccarelli C; Marampon F; Scoglio A; Mauro A; Giacinti C; De Cesaris P; Zani BM
    Mol Cancer; 2005 Dec; 4():41. PubMed ID: 16351709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
    Marampon F; Ciccarelli C; Zani BM
    Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma.
    Marampon F; Bossi G; Ciccarelli C; Di Rocco A; Sacchi A; Pestell RG; Zani BM
    Mol Cancer Ther; 2009 Mar; 8(3):543-51. PubMed ID: 19258428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals.
    Marampon F; Gravina GL; Di Rocco A; Bonfili P; Di Staso M; Fardella C; Polidoro L; Ciccarelli C; Festuccia C; Popov VM; Pestell RG; Tombolini V; Zani BM
    Mol Cancer Ther; 2011 Jan; 10(1):159-68. PubMed ID: 21220498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells.
    Megiorni F; Gravina GL; Camero S; Ceccarelli S; Del Fattore A; Desiderio V; Papaccio F; McDowell HP; Shukla R; Pizzuti A; Beirinckx F; Pujuguet P; Saniere L; der Aar EV; Maggio R; De Felice F; Marchese C; Dominici C; Tombolini V; Festuccia C; Marampon F
    J Hematol Oncol; 2017 Oct; 10(1):161. PubMed ID: 28985758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines.
    Marampon F; Gravina GL; Popov VM; Scarsella L; Festuccia C; La Verghetta ME; Parente S; Cerasani M; Bruera G; Ficorella C; Ricevuto E; Tombolini V; Di Cesare E; Zani BM
    Int J Oncol; 2014 Jan; 44(1):285-94. PubMed ID: 24189697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo.
    Ciccarelli C; Di Rocco A; Gravina GL; Mauro A; Festuccia C; Del Fattore A; Berardinelli P; De Felice F; Musio D; Bouché M; Tombolini V; Zani BM; Marampon F
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1685-1699. PubMed ID: 29959569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines.
    Miranda MB; McGuire TF; Johnson DE
    Leukemia; 2002 Apr; 16(4):683-92. PubMed ID: 11960350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres.
    Walter D; Satheesha S; Albrecht P; Bornhauser BC; D'Alessandro V; Oesch SM; Rehrauer H; Leuschner I; Koscielniak E; Gengler C; Moch H; Bernasconi M; Niggli FK; Schäfer BW;
    PLoS One; 2011; 6(5):e19506. PubMed ID: 21602936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma.
    Wiesenauer CA; Yip-Schneider MT; Wang Y; Schmidt CM
    J Am Coll Surg; 2004 Mar; 198(3):410-21. PubMed ID: 14992744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
    Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
    J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1α functional interplay.
    Marampon F; Gravina GL; Zani BM; Popov VM; Fratticci A; Cerasani M; Di Genova D; Mancini M; Ciccarelli C; Ficorella C; Di Cesare E; Festuccia C
    Int J Oncol; 2014 Jun; 44(6):2121-31. PubMed ID: 24676782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-Myc Sustains Transformed Phenotype and Promotes Radioresistance of Embryonal Rhabdomyosarcoma Cell Lines.
    Gravina GL; Festuccia C; Popov VM; Di Rocco A; Colapietro A; Sanità P; Monache SD; Musio D; De Felice F; Di Cesare E; Tombolini V; Marampon F
    Radiat Res; 2016 Apr; 185(4):411-22. PubMed ID: 27104757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126.
    Eppstein AC; Sandoval JA; Klein PJ; Woodruff HA; Grosfeld JL; Hickey RJ; Malkas LH; Schmidt CM
    J Pediatr Surg; 2006 Jan; 41(1):252-9. PubMed ID: 16410143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disulfiram eradicates tumor-initiating hepatocellular carcinoma cells in ROS-p38 MAPK pathway-dependent and -independent manners.
    Chiba T; Suzuki E; Yuki K; Zen Y; Oshima M; Miyagi S; Saraya A; Koide S; Motoyama T; Ogasawara S; Ooka Y; Tawada A; Nakatsura T; Hayashi T; Yamashita T; Kaneko S; Miyazaki M; Iwama A; Yokosuka O
    PLoS One; 2014; 9(1):e84807. PubMed ID: 24454751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphoprotein analysis reveals MEK inhibition as a way to target non-small cell lung cancer tumor initiating cells.
    Lundholm L; Hååg P; Juntti T; Lewensohn R; Viktorsson K
    Int J Radiat Biol; 2014 Aug; 90(8):718-26. PubMed ID: 24646078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABCG2 protects kidney side population cells from hypoxia/reoxygenation injury through activation of the MEK/ERK pathway.
    Liu WH; Liu HB; Gao DK; Ge GQ; Zhang P; Sun SR; Wang HM; Liu SB
    Cell Transplant; 2013; 22(10):1859-68. PubMed ID: 23032069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.